Educational material about research-use reagents; not instructions for human use.

A search for Zepbound (also seen transliterated as "zepbaund" in Cyrillic-script markets) usually means the US prescription brand for weight management, not INN tirzepatide on an RUO vial. Below: how Zepbound differs from Mounjaro even though the active ingredient is the same molecule, which FDA indications each brand actually holds (Zepbound now has two, and the second only arrived in December 2024), and where the pharmacy brand ends and the research sample begins.

Zepbound and Mounjaro: one molecule, two brands, different FDA indications

Zepbound and Mounjaro are trademarks for injectable drug products from Eli Lilly. The active ingredient in both is tirzepatide (INN), a synthetic dual incretin agonist peptide.

The FDA approved these two brands for DIFFERENT indications at DIFFERENT times, even though the molecule is identical. Mounjaro was approved on May 13, 2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Zepbound received a separate approval on November 8, 2023 for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with a weight-related condition, per the FDA.

The indication list grew after both brands were already on the market. On December 20, 2024, Zepbound received a second, separate FDA approval, this time for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, the first and, at the time of approval, only medication cleared for that indication, per a short report in JAMA. The decision rested on two SURMOUNT-OSA trials: over 52 weeks, tirzepatide reduced the apnea-hypopnea index (AHI) by an average of 25.3 events per hour versus 5.3 with placebo, from a baseline AHI of roughly 51.5 events per hour, according to NEJM. Mounjaro carries no such second indication; it remains approved only for glycemic control in type 2 diabetes.

The Longeva hub does not sell Zepbound, Mounjaro, or other pharmacy brands. We publish trademark editorials on the apex; the commercial GLP-1/GIP RUO sample lives under Incretin: tirzepatide card.

Dual GIP/GLP-1: why one molecule ships under two names

Tirzepatide activates two incretin-system receptors at once, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). That is exactly why the same molecule can be registered under different brands for different clinical uses: the pharmacology stays the same, while the approved indication, dosing, and trademark belong to a separate regulatory filing.

  • GLP-1 axis. Satiety, gastric emptying, glucose-dependent insulin, the same logic shared with semaglutide.
  • GIP axis. A second incretin pathway that mono-GLP-1 drugs like Ozempic do not activate.
  • Third axis (glucagon). Not present in tirzepatide; triple agonism with glucagon is retatrutide on Tripept. Map of all three axes: GLP-1, GIP and glucagon.

The SURMOUNT program (body weight), which Zepbound's approval is based on, and the SURPASS program (type 2 diabetes), which Mounjaro's approval is based on, both studied branded prescription tirzepatide. That is class context, not an RUO protocol. A detailed breakdown of both programs, SURPASS-2 and SURMOUNT-1, lives in Longeva's own native article: SURPASS-2 and SURMOUNT-1, research context.

The actual SURPASS-2 numbers show how far apart the two molecules land. In a head-to-head comparison, tirzepatide (as Mounjaro) was tested against semaglutide 1 mg, the dose registered for Ozempic, in 1,879 patients with type 2 diabetes over 40 weeks: tirzepatide outperformed on HbA1c at all three doses (a 2.01 to 2.30 percentage-point reduction versus 1.86 for semaglutide) and produced greater weight loss (a 1.9 to 5.5 kg difference favoring tirzepatide, depending on dose), reports NEJM. For help choosing which molecule fits a given research question, see Tirzepatide vs semaglutide: choosing a research sample.

Zepbound, Mounjaro, Ozempic: how they differ

BrandINNMakerFDA indicationApproval date
ZepboundtirzepatideEli Lillychronic weight management;
sleep apnea (OSA)		2023-11-08;
2024-12-20
MounjarotirzepatideEli Lillytype 2 diabetes2022-05-13
Ozempic / WegovysemaglutideNovo Nordiskdiabetes / weightdifferent molecule
RUO tirzepatidetirzepatideresearch supplierlab sample, not a drug productnot applicable

Zepbound and Mounjaro share the same molecule (tirzepatide) under different brand lines and registered indications. Ozempic is a different molecule (semaglutide) with a different receptor profile. Wegovy is the same semaglutide as Ozempic, just under a different name and at the dose registered for weight management: Wegovy and semaglutide. Full trademark breakdown for Mounjaro: Mounjaro (tirzepatide); comparison with Ozempic: Mounjaro vs Ozempic; why Ozempic is not tirzepatide: Ozempic and semaglutide.

Trademark versus INN: why "Zepbound" does not belong on a research vial

An INN (International Nonproprietary Name), tirzepatide in this case, is assigned by the World Health Organization and is an open name for the substance that anyone can use. A trademark, by contrast, is a specific manufacturer's mark on a specific registered product: Zepbound and Mounjaro belong to Eli Lilly, and no other supplier, research included, has any right to print those words on its own label. A seller who writes "Zepbound" on a research-use vial infringes the trademark and misleads the buyer about what is actually inside at the same time.

The FDA also warns against a different kind of mixing. Zepbound's current label, updated alongside the OSA approval, states that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended, per DailyMed, the official mirror of the FDA label. So even Zepbound and Mounjaro, despite sharing one molecule, are not positioned as interchangeable within the same course of treatment, and that status certainly does not carry over to research-grade tirzepatide.

One more layer of context is legal access to the molecule itself. Tirzepatide injection products were added to the FDA's drug shortage list on December 15, 2022; the agency confirmed the shortage was resolved in a declaratory order dated December 19, 2024, and set a wind-down period for compounding pharmacies: 60 days, until February 18, 2025, for pharmacies compounding under section 503A, and 90 days, until March 19, 2025, for larger 503B outsourcing facilities, per the official FDA document. That is the legal pharmacy route to tirzepatide in the US, and it is a separate track from the RUO segment, which was never part of the regulated shortage supply and is not subject to these rules.

Within the research segment itself, other trade names from various suppliers show up too, names like "Tirzetta" and similar ones, sold under the same INN tirzepatide. None of them is an FDA brand, and a name on a research-use label proves nothing by itself, whether it reads "Zepbound," "zepbaund," or something else entirely. The verification rule stays the same regardless of the name on the vial: the batch's own COA, not the text on the label.

"Zepbound analogues" in search: two different paths

When people search for "Zepbound analogues" or "buy Zepbound," they usually mean one of two things:

  1. Other prescription incretin drugs, Mounjaro (same molecule, different indication), Ozempic, Wegovy, Saxenda. The pharmacy path: prescription, country-specific registration, price.
  2. Research-use tirzepatide, the same INN molecule as a lyophilized research reagent without brand markup, but also without pharmacy-grade quality guarantees. Label status: Research Use Only (RUO), not for human use.

Longeva covers the second layer, the laboratory context. Incretin runs the commercial GLP-1 and GIP catalogue, while this side keeps the navigation between trademarks, monographs, and sample cards. The research tirzepatide sample on Incretin and its link to the wiki: tirzepatide, research sample and wiki. Weight-loss selection: peptides for weight loss.

How to verify tirzepatide purity: COA and batch checks

An independent check means the seller of the batch sends the sample for analysis itself, not the raw-material supplier, and the lab does not know in advance what result is "expected." In this space, independent third-party labs such as Janoshik, Testides, Uzorak, or North American Diagnostics are the ones doing this kind of testing: they verify the substance's identity (typically by mass spectrometry or HPLC) and its purity percentage separately from the manufacturer. Tirzepatide batches in the Longeva catalogue are accompanied by this kind of analysis and published in the open COA archive.

  • COA (Certificate of Analysis) per batch (LOT): identity and purity from a third-party lab test. A listing titled "Zepbound" with no COA does not prove the vial actually contains tirzepatide.
  • LOT match. The batch number on the vial must match the PDF in the COA archive; verify at /verify/{lot}.
  • Red flags: no COA; one certificate covering every batch; messenger-only seller; a price far below market for the claimed purity; a relabeled vial with a brand name and no lab document.

Same rule as semaglutide and liraglutide: verifiable purity beats price. A vial labeled Zepbound is still a fake without an independent COA.

Frequently asked questions about Zepbound

How is Zepbound different from Mounjaro?

Not at the molecule level: both drugs contain tirzepatide. The difference is regulatory. Mounjaro was approved on May 13, 2022 for glycemic control in type 2 diabetes; Zepbound followed separately on November 8, 2023, for weight management. Two brand names, two labels, one active ingredient.

How is Zepbound different from Ozempic?

They are different molecules. Zepbound contains tirzepatide, a dual GIP/GLP-1 agonist; Ozempic contains semaglutide, a GLP-1-only agonist. In a head-to-head trial within the diabetes program, SURPASS-2, tirzepatide produced greater HbA1c and weight reductions than semaglutide 1 mg, the dose registered specifically for Ozempic.

How is Zepbound different from Wegovy?

Wegovy, like Ozempic, is semaglutide, just under a different brand name and at the dose registered for weight management. The Wegovy/Ozempic pair mirrors the Zepbound/Mounjaro pair: one molecule, two brand names for two indications, only built on semaglutide rather than tirzepatide.

Can Mounjaro be swapped for Zepbound, or the other way around?

That is a physician's call, not a self-directed substitution. Each product carries its own registration, its own label, and its own dose-escalation schedule for its own indication. Zepbound's current label specifically advises against coadministration with other tirzepatide-containing products, so the two are not positioned as interchangeable within one treatment course.

What else, besides weight management, is Zepbound approved for?

As of December 2024, moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, the first and, at the time, only drug approved for that indication. This is a second, separate approval added on top of the 2023 weight-management indication, not a replacement for it.

What is RUO tirzepatide, and how does it differ from Zepbound?

RUO (Research Use Only) tirzepatide is the same INN molecule sold as a laboratory reagent, with no pharmacy registration, no clinical manufacturing oversight, and no clearance for use in humans. Zepbound is a registered prescription drug with a specific FDA-approved indication, dosing, and label. The two share only the chemical structure of the active ingredient; their legal and quality status is entirely different.

Price and status in Ukraine

Zepbound is a newer brand than Mounjaro and holds a narrower registration: the FDA cleared it for the US market specifically for weight management (and now sleep apnea too). We found no confirmed official registration of Zepbound in Ukraine, so any claim about a pharmacy price or local availability would be unfounded. Research-use tirzepatide stays available as a research option regardless of a given pharmacy brand's registration status in any particular country, but it shifts all quality responsibility to the buyer: COA and LOT checks become mandatory, not a nice extra.

Trademarks. Zepbound® and Mounjaro® belong to Eli Lilly; Ozempic®, Wegovy®, and Rybelsus® belong to Novo Nordisk; Saxenda® and Victoza® belong to Novo Nordisk. Longeva is not affiliated with these manufacturers and does not sell their drug products.